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Abstract: The purpose of the present one-year follow-up study was to describe and investigate the change in the amount 
of antipsychotic drugs prescribed for ACT (assertive community treatment) clients in Japan. Subjects were 52 clients of 
ACT from January 2009 to December 2009. Prescription data were collected each month from the time the clients entered 
into ACT. The results of a Wilcoxon signed-rank test show that the dosage of antipsychotics significantly decreased from 
1,131.3 mg to 731.3 mg over the course of the 12 months (Z = -2.505, p = 0.012). 
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INTRODUCTION  
High-dose treatments of antipsychotic drugs are not safe 
because they may cause cardiac arrest and even sudden death 
[1]. Moreover, treatment with atypical antipsychotics may 
increase the risk of metabolic syndrome and diabetes. Meta-
bolic syndrome often encompasses medical conditions such 
as weight gain, hypertriglyceridemia, and increased insulin, 
glucose, and low-density lipoprotein cholesterol levels [2]. 
Polypharmacy of antipsychotics also can have clear adverse 
consequences, including early death [3]. Although the im-
portance of simplifying prescriptions has been recognized, 
polypharmacy for schizophrenia patients remains prevalent 
[4]. 
Due to Japan’s long history with a national health insur-
ance system, Japanese patients are usually referred to psy-
chiatric hospitals rather than community treatment. The du-
ration of hospitalization in Japan is generally long and psy-
chiatrists often prescribe multiple antipsychotic drugs. This 
form of polypharmacy results in higher doses because of the 
additive effects of two or more antipsychotic drugs pre-
scribed concurrently[5].  
Assertive community treatment (ACT) is a well-
documented, evidence-based case management program [6]. 
ACT provides a highly individualized and comprehensive 
array of services with integrated medical and rehabilitation 
services delivered by an interdisciplinary team in the com-
munity. In May 2003, the first experimental adoption of 
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ACT was initiated in Chiba, Japan [7, 8]. Considering the 
high doses of antipsychotic drugs prescribed concurrently in 
Japan, it is important to evaluate the change in antipsychotic 
medication for clients of ACT.  
The purpose of the present one-year follow-up study was 
to describe and investigate the change in the amount of an-
tipsychotic drugs prescribed for ACT clients. 
METHODS 
Subject 
Study subjects were clients of ACT from January, 2009 
to December, 2009. Of the 60 clients of ACT on December 
31, 2009, 52 had entered into ACT before January 1, 2009. 
All 52 clients gave written informed consent to participate in 
the research. 
Setting 
The ACT program in this study is operated in a suburban 
area near Tokyo. The similarity of the ACT program to the 
original ACT model was measured by the Dartmouth Asser-
tive Community Treatment Scale (DACTS) [9]. The DACTS 
consists of 28 items on a 5-point Likert scale with higher 
scores indicating higher similarity. The average ACT pro-
gram score for January, 2010 was 4.3. Thus, this appears to 
be a well-implemented program that is in line with interna-
tional standards. 
The Research Ethics Board of the International Medical 
Center of Japan approved this study. 
Prescription Data 
Prescription data were collected each month beginning 
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after entry. The average daily dose was established for each 
antipsychotic medication and converted to the relative po-
tency equivalent of 100 mg of chlorpromazine (CPZeq). 
Doses equivalent to 100 mg/day of chlorpromazine were 2 
mg/day for risperidone and 5 mg/day for olanzapine. These, 
and the equivalencies of other antipsychotic medications, 
were based on information published in the literature [10, 
11]. Polypharmacy was defined as the co-prescription of two 
or more antipsychotic medications. 
Statistical Analysis 
Because the variances of CPZeq were skewed, a Wil-
coxon signed-rank test was utilized to compare them be-
tween the baseline and 12 months after baseline. Statistic 
calculations were performed using PASW 17.0. 
RESULTS 
The average age of subjects was 44.7 (SD = 11.7) years; 
48.1% of clients were male. Psychiatric diagnoses included 
schizophrenia or a related disorder (39 clients, or 75.0%), 
affective disorders or a related disorder (8 clients, or 15.4 
%), and other disorders (5 clients, or 9.6 %). The average 
number of hospitalizations before participation in ACT was 
4.3 (SD = 3.2). The average length of time clients served in 
ACT was 36.7 months (SD = 21.7) and 32 out of 52 (61.5%) 
clients had no experience of admission to the hospital during 
this period. 
Fig. (1) shows the mean, median, and first and third quar-
tiles for the total dosage of antipsychotics received each 
month between baseline and 12 months after baseline. The 
total dosage of antipsychotics decreased over the year during 
which the study took place. The results of the Wilcoxon 
signed-rank test show that the dosage of antipsychotics sig-
nificantly decreased from 1131.3 mg to 731.3 mg (Z =   
-2.505, p = 0.012) over the course of the 12 months. 
The results of the Chi square test showed that the number 
of clients who were receiving dosages of antipsychotics 
above 1000 mg was significantly decreased from 21 (40.4%) 
at baseline to 14 (26.9%) at 12 months after baseline (Chi-
square = 16.4, p < .001). 
At baseline, 27 (54.0%) of the 50 clients were prescribed 
polypharmacy and at 12 months after baseline 30 (60.0%) 
clients were prescribed polypharmacy. In terms of prescrip-
tion patterns, there was no significant difference between 
these two periods. 
DISCUSSIONS 
The dosage of antipsychotic drugs for clients of ACT 
significantly decreased one year after they had been referred 
to an ACT team. Excessive dosing refers to doses greater 
than the optimal daily dosage of 1000 mg of chlorpromazine 
or the equivalent of another antipsychotic [12]. The results 
showed that the number of clients who received excessive 
doses was also significantly decreased. These decreases were 
made possible by the intensive and integrated care of ACT as 
well as the close communication between the prescriber and 
the case managers who monitor clients’ daily living in the 
community setting. 
 
Fig. (1). Change of dosage of antipsychotics (CPZeq). 
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These results should be cautiously interpreted because 
there are limitations. A major limitation is the lack of control 
groups and the fact that clinical outcomes of the treatment, 
such as clients’ symptoms, QOLs, social functioning, or 
other outcomes, were not evaluated. It is difficult to deter-
mine whether the reduction of the dosage of antipsychotic 
drugs were due to the ACT intervention or some other cause. 
However, previous results show that ACT effectively re-
duced the costs of hospital care, while improving outcomes 
and client satisfaction for people with severe mental illnesses 
[6, 7]. We suggest that the reduction of antipsychotic drug 
dosage did not bring about adverse effects for clients. Be-
cause we only measured subjects in one ACT program, gen-
eralization of these findings is limited; however, ACT pro-
grams share a common structure of services based on inter-
nationally disseminated standards, and it is possible to apply 
the findings of this study to other ACT programs. 
In conclusion, the present study demonstrated a reduction 
in antipsychotic drug dosage for ACT clients in Japan. We 
suggest that ACT could have a positive influence for clients 
trying to recover in the community without an excessive 
amount of antipsychotic drugs. 
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